

Serial No. 09/674,815
5836-01-MJA (PC17416)AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-31 (cancelled)

RECEIVED
CENTRAL FAX CENTER

SEP 28 2006

Claim 32 (withdrawn): The composition of Claim 25 wherein the 4-amino-3-substituted-butanoic acid derivative is pregabalin.

Claim 33 (cancelled)

Claim 34 (currently amended): A pharmaceutical composition comprising:

- (a) [[an]] a neutral α amino acid, and
- (b) a 4-amino-3-substituted-butanoic acid derivative selected from the group consisting of gabapentin and pregabalin,
wherein the pharmaceutical composition is a solid.

Claim 35 (currently amended): The composition of Claim 34, wherein the neutral α -amino acid is one or more selected from: glycine, phenylglycine, hydroxyphenylglycine, dihydroxyphenylglycine, L-alanine, hydroxy-L-alanine, L-leucine, hydroxy-L-leucine, dihydroxy-L-leucine, L-norleucine, methylene-L-norleucine, L-ketonorleucine, L-isoleucine, hydroxy-L-isoleucine, dihydroxy-L-isoleucine, L-valine, hydroxy-L-valine, L-isovaline, L-norvaline, hydroxy-L-norvaline, hydroxy-L-ketonorvaline, L-methionine, L-homomethionine, L-ethionine, L-threonine, acetyl-L-threonine, L-tryptophan, hydroxy-L-tryptophan, methyl-L-tryptophan, L-tyrosine, hydroxy-L-tyrosine, methyl-L-tyrosine, bromo-L-tyrosine, dibromo-L-tyrosine, 3,5-diiodo-L-tyrosine, acetyl-L-tyrosine, chloro-L-tyrosine, L-m-tyrosine, L-levodopa, L-methyldopa, L-thyroxine, L-serine, acetyl-L-serine, L-homoserine, acetyl-L-homoserine, ethyl-L-homoserine, propyl-L-homoserine, butyl-L-homoserine, L-cystine, L-homocystine, methyl-L-cysteine, allyl-L-cysteine, propyl-L-cysteine, L-phenylalanine, dihydro-L-phenylalanine.

(Page 2 of 13)

Serial No. 09/674,815
5836-01-MJA (PC17416)

hydroxymethyl-L-phenylalanine, L-aminobutyric acid, L-aminoisobutyric acid, L-ketoaminobutyric acid, dichloro-L-aminobutyric acid, dihydroxy-L-aminobutyric acid, phenyl-L-aminobutyric acid, L-aminovaleric acid, L-aminohydroxyvaleric acid, dihydroxy-L-aminovaleric acid, L-aminoisovaleric acid, L-aminohexanoic acid, methyl-L-aminohexanoic acid, L-aminoheptanoic acid, L-aminoctanoic acid, and citrulline, and the D- and DL-forms thereof;

- L, D and DL forms of neutral α -amino acids;
alkali salts, acid amides, alkyl substituted derivatives of acid amides or alkyl esters of the L, D and DL forms of acidic α -amino acids;
acid addition salts or monoacylated derivatives of the L, D and DL forms of basic α -amino acids;
 α,ω diaminodicarboxylic acids; and
acidic amino acid basic amino acid adducts of the L, D and DL forms of acidic α -amino acids and the L, D and DL forms of basic α -amino acids.

Claim 36 (currently amended): The composition of Claim [[34]] 35, wherein the neutral α -amino acid is one or more selected from:

glycine, phenylglycine, hydroxyphenylglycine, dihydroxyphenylglycine, L-alanine, hydroxy-L-alanine, L-leucine, hydroxy-L-leucine, dihydroxy-L-leucine, L-isoleucine, hydroxy-L-isoleucine, dihydroxy-L-isoleucine, L-valine, hydroxy-L-valine, L-isovaline, and the D- and DL-forms thereof.

neutral α -amino acids consisting of glycine, phenylglycine, hydroxyphenylglycine, dihydroxyphenylglycine, L-alanine, hydroxy-L-alanine, L-leucine, hydroxy-L-leucine, dihydroxy-L-leucine, L-norleucine, methylene-L-norleucine, L-ketonorleucine, L-isoleucine, hydroxy-L-isoleucine, dihydroxy-L-isoleucine, L-valine, hydroxy-L-valine, L-isovaline, L-norvaline, hydroxy-L-norvaline, hydroxy-L-ketonorvaline, L-methionine, L-homomethionine, L-cysteine, L-threonine, acetyl-L-threonine, L-tryptophan, hydroxy-L-tryptophan, methyl-L-tryptophan, L-tyrosine, hydroxy-L-tyrosine, methyl-L-tyrosine, bromo-L-tyrosine, dibromo-L-tyrosine, 3,5-diiodo-L-tyrosine, acetyl-L-tyrosine, chloro-L-tyrosine, L-m-tyrosine, L-levodopa, L-

Serial No. 09/674,815
5836-01-MJA (PC17416)

~~methyl~~dopa, L-thyroxine, L-serine, acetyl L-serine, L-homoserine, acetyl L-homoserine, ethyl L-homoserine, propyl L-homoserine, butyl L-homoserine, L-cystine, L-homocystine, methyl L-cysteine, allyl L-cysteine, propyl L-cysteine, L-phenylalanine, dihydro L-phenylalanine, hydroxymethyl L-phenylalanine, L-aminobutyric acid, L-aminoisobutyric acid, L-ketoaminobutyric acid, dichloro L-aminobutyric acid, dihydroxy L-aminobutyric acid, phenyl L-aminobutyric acid, L-aminovaleric acid, L-aminohydroxyvaleric acid, dihydroxy L-aminovaleric acid, L-aminoisovaleric acid, L-aminohexanoic acid, methyl L-aminohexanoic acid, L-aminoheptanoic acid, L-aminooctanoic acid and citrulline and the D- and DL-forms thereof;

acidic α -amino acids consisting of L-aspartic acid, L-glutamic acid, L-carbo cysteine, L-aminoglutamic acid, L-aminosuccinic acid, L-aminoadipic acid, L-aminopimelic acid, hydroxy L-aminopimelic acid, methyl L-aspartic acid, hydroxy L-aspartic acid, methyl L-glutamic acid, methyl hydroxy L-glutamic acid, L-methyleneglutamic acid, hydroxy L-glutamic acid, dihydroxy L-glutamic acid and hydroxy L-aminoadipic acid and the D- and DL-forms thereof;

basic α -amino acids consisting of L-arginine, L-lysine, L-ornithine, L-canavanine, L-eanaline, hydroxy L-lysine, L-homoarginine, hydroxy L-homoarginine, hydroxy L-ornithine, L-diaminopropionic acid, L-diaminohexanoic acid, L-diaminobutyric acid, L-diamovaleric acid, L-diaminoheptanoic acid, and L-diaminoctanoic acid and the D- and DL-forms thereof; and

α,ω -diaminodicarboxylic acids consisting of diaminosuccinic acid, diaminoglutamic acid, diaminoadipic acid and diaminopimelic acid;

provided that, when said α -amino acid is an adipic α -amino acid, it is used in the form of the corresponding alkali salt, acid amide, alkyl substituted derivative of acid amide or alkyl ester thereof, or when said α -amino acid is a basic α -amino acid, it is used in the form of the corresponding acid addition salt or monoacylated derivative thereof, or

said acidic α -amino acid and said basic α -amino acid are also used in the form of the corresponding acidic amino acid-basic amino acid adduct.

Claim 37 (currently amended): The composition of Claim 34, wherein a total amount of the neutral α -amino acid is in the range of 0.001 - 80 moles per mole of the 4-amino-3-substituted-butanoic acid derivative.

(Page 4 of 13)

Serial No. 09/674,815
5836-01-MJA (PC17416)

Claim 38 (previously presented): The composition of Claim 34, wherein the 4-amino-3-substituted-butanoic acid derivative is gabapentin.

Claim 39 (cancelled)

(Page 5 of 13)

PAGE 6/14 * RCVD AT 9/28/2006 3:49:54 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-3/19 * DNI:2738300 * CSID:7346221269 * DURATION (mm:ss):04:38